This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Nestorone and ethinyl estradiol contraceptive vaginal ring
Drug Names(s): NES/EE CVR
Description: The Nestorone/ethinyl estradiol contraceptive vaginal ring is designed to simultaneously release Nestorone along with a low dose of ethinyl estradiol for up to 13 cycles (one full year). The ring remains in the vagina for three weeks per cycle, followed by one ring-free week.
Nestorone is a nonandrogenic, 19-norprogesterone derivative and ethinyl estradiol is an orally bio-active estrogen.
Deal Structure: The NES/EE contraceptive ring was originally developed by the Population Council, an international, nonprofit, nongovernmental research organization.
Population Council and Watson
In March 2010, Watson Pharmaceuticals licensed the commercial rights to the NES/EE ring in the United States, Canada and Mexico. Under the terms of the agreement, Watson will pay the Population Council an undisclosed licensing fee and make additional payments based on the achievement of certain regulatory and sales performance milestones. If the product is successfully commercialized, Watson also will pay royalties based on sales in the United States, Canada, and Mexico.
In January 2013, Watson changed its name to Actavis.
Actavis and Allergan
In June 2015, Actavis announced that the company has adopted Allergan as its new global name and will begin trading under a new symbol (AGN). The company name change follows the acquisition of Allergan in March 2015 and the...See full deal structure in Biomedtracker
Nestorone and ethinyl estradiol contraceptive vaginal ring News
Additional information available to subscribers only: